Francisco Veiga

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2893534/publications.pdf

Version: 2024-02-01

241 papers	12,135 citations	20759 60 h-index	33814 99 g-index
246 all docs	246 docs citations	246 times ranked	13464 citing authors

#	Article	IF	Citations
1	Osteosarcoma from the unknown to the use of exosomes as a versatile and dynamic therapeutic approach. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 170, 91-111.	2.0	6
2	Nano- and microparticle-stabilized Pickering emulsions designed for topical therapeutics and cosmetic applications. International Journal of Pharmaceutics, 2022, 615, 121455.	2.6	31
3	Nanomaterials in hair care and treatment. Acta Biomaterialia, 2022, 142, 14-35.	4.1	18
4	Nanocarrier-based dermopharmaceutical formulations for the topical management of atopic dermatitis. International Journal of Pharmaceutics, 2022, 618, 121656.	2.6	18
5	Trichilia catigua and Turnera diffusa phyto-phospholipid nanostructures: Physicochemical characterization and bioactivity in cellular models of induced neuroinflammation and neurotoxicity. International Journal of Pharmaceutics, 2022, 620, 121774.	2.6	4
6	Nanocarriers for the topical treatment of psoriasis - pathophysiology, conventional treatments, nanotechnology, regulatory and toxicology. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 176, 95-107.	2.0	17
7	Where Is Nano Today and Where Is It Headed? A Review of Nanomedicine and the Dilemma of Nanotoxicology. ACS Nano, 2022, 16, 9994-10041.	7.3	62
8	Polymeric and metal nanostructures for bone regeneration and osteomyelitis treatment. , 2022, , 605-644.		0
9	Macrophage Cell Membraneâ€Cloaked Nanoplatforms for Biomedical Applications. Small Methods, 2022, 6, .	4.6	58
10	Co-Delivery of erlotinib and resveratrol via nanostructured lipid Carriers: A synergistically promising approach for cell proliferation prevention and ROS-Mediated apoptosis activation. International Journal of Pharmaceutics, 2022, 624, 122027.	2.6	15
11	Plant-mediated green synthesis of metal-based nanoparticles for dermopharmaceutical and cosmetic applications. International Journal of Pharmaceutics, 2021, 597, 120311.	2.6	104
12	Recent advances in peptide-targeted micelleplexes: Current developments and future perspectives. International Journal of Pharmaceutics, 2021, 597, 120362.	2.6	4
13	Trichilia catigua and Turnera diffusa extracts: In vitro inhibition of tyrosinase, antiglycation activity and effects on enzymes and pathways engaged in the neuroinflammatory process. Journal of Ethnopharmacology, 2021, 271, 113865.	2.0	12
14	Ethosomes as Nanocarriers for the Development of Skin Delivery Formulations. Pharmaceutical Research, 2021, 38, 947-970.	1.7	74
15	Preclinical developments of natural-occurring halloysite clay nanotubes in cancer therapeutics. Advances in Colloid and Interface Science, 2021, 291, 102406.	7.0	26
16	Unleashing the potential of cell membrane-based nanoparticles for COVID-19 treatment and vaccination. Expert Opinion on Drug Delivery, 2021, 18, 1395-1414.	2.4	14
17	Nanotechnology-based formulations toward the improved topical delivery of anti-acne active ingredients. Expert Opinion on Drug Delivery, 2021, 18, 1435-1454.	2.4	8
18	Emerging role of nanoclays in cancer research, diagnosis, and therapy. Coordination Chemistry Reviews, 2021, 440, 213956.	9.5	56

#	Article	IF	Citations
19	Development of nanostructured systems using natural polymers to optimize the treatment of inflammatory bowel diseases: A prospective study. Journal of Drug Delivery Science and Technology, 2021, 64, 102590.	1.4	7
20	Prevention of UV-induced skin cancer in mice by gamma oryzanol-loaded nanoethosomes. Life Sciences, 2021, 283, 119759.	2.0	15
21	Transport properties of aqueous solutions of the oncologic drug 5-fluorouracil: A fundamental complement to therapeutics. Journal of Chemical Thermodynamics, 2021, 161, 106533.	1.0	5
22	Cyclodextrin-based delivery systems for in vivo-tested anticancer therapies. Drug Delivery and Translational Research, 2021, 11, 49-71.	3.0	46
23	Multifunctional polymeric micelle-based nucleic acid delivery: Current advances and future perspectives. Applied Materials Today, 2021, 25, 101217.	2.3	21
24	Synthesis and Characterization of a Novel Nanomicellar System Pluronic-PEI Suitable for Gene and Drug Co-Delivery in Cancer Therapy. Proceedings (mdpi), 2021, 78, 36.	0.2	0
25	Polymeric Micelles: A Promising Pathway for Dermal Drug Delivery. Materials, 2021, 14, 7278.	1.3	21
26	Dendrimers as Pharmaceutical Excipients: Synthesis, Properties, Toxicity and Biomedical Applications. Materials, 2020, 13, 65.	1.3	177
27	Progressing Towards the Sustainable Development of Cream Formulations. Pharmaceutics, 2020, 12, 647.	2.0	14
28	Melanin nanoparticles as a promising tool for biomedical applicationsÂâ€“ a review. Acta Biomaterialia, 2020, 105, 26-43.	4.1	89
29	Pluronic-based nanovehicles: Recent advances in anticancer therapeutic applications. European Journal of Medicinal Chemistry, 2020, 206, 112526.	2.6	45
30	Sterculia striata gum as a potential oral delivery system for protein drugs. International Journal of Biological Macromolecules, 2020, 164, 1683-1692.	3.6	24
31	Electro-responsive controlled drug delivery from melanin nanoparticles. International Journal of Pharmaceutics, 2020, 588, 119773.	2.6	11
32	Rheology by Design: A Regulatory Tutorial for Analytical Method Validation. Pharmaceutics, 2020, 12, 820.	2.0	35
33	Biomimetic cancer cell membrane-coated nanosystems as next-generation cancer therapies. Expert Opinion on Drug Delivery, 2020, 17, 1515-1518.	2.4	20
34	An Overview of Exosomes in Cancer Therapy: A Small Solution to a Big Problem. Processes, 2020, 8, 1561.	1.3	7
35	Micelleplexes: A Promising Nanocarrier for the Transport of Genetic Material and Drugs. , 2020, , 267-287.		1
36	The potential of micelleplexes as a therapeutic strategy for osteosarcoma disease. 3 Biotech, 2020, 10, 147.	1.1	12

#	Article	IF	Citations
37	Micelleplex-based nucleic acid therapeutics: From targeted stimuli-responsiveness to nanotoxicity and regulation. European Journal of Pharmaceutical Sciences, 2020, 153, 105461.	1.9	15
38	Development of a Platform to Align Education and Practice: Bridging Academia and the Profession in Portugal. Pharmacy (Basel, Switzerland), 2020, 8, 11.	0.6	4
39	Nanomedicine in osteosarcoma therapy: Micelleplexes for delivery of nucleic acids and drugs toward osteosarcoma-targeted therapies. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 148, 88-106.	2.0	21
40	Complex Polysaccharide-Based Nanocomposites for Oral Insulin Delivery. Marine Drugs, 2020, 18, 55.	2.2	16
41	Topical Minoxidil-Loaded Nanotechnology Strategies for Alopecia. Cosmetics, 2020, 7, 21.	1.5	38
42	miR-29b and retinoic acid co-delivery: a promising tool to induce a synergistic antitumoral effect in non-small cell lung cancer cells. Drug Delivery and Translational Research, 2020, 10, 1367-1380.	3.0	11
43	Micelleplexes as nucleic acid delivery systems for cancer-targeted therapies. Journal of Controlled Release, 2020, 323, 442-462.	4.8	41
44	OraÃ§Ãµes de SapiÃªncia da Faculdade de FarmÃ¡cia da Universidade de Coimbra 1921 - 2020. , 2020, , .		0
45	Development and Characterization of a Novel Mixed Polymeric Micelle as a Potential Therapeutic Strategy for Osteosarcoma. Proceedings (mdpi), 2020, 78, .	0.2	0
46	Surface functionalization of PLGA nanoparticles for drug delivery. , 2020, , 185-203.		2
47	Study of the effect of solvent on acetylate cashew gum-based nanoparticles properties and antimicrobial activity. Revista Materia, 2020, 25, .	0.1	0
48	Extraction of phospholipid-rich fractions from egg yolk and development of liposomes entrapping a dietary polyphenol with neuroactive potential. Food and Chemical Toxicology, 2019, 133, 110749.	1.8	22
49	Nanocarriers for resveratrol delivery: Impact on stability and solubility concerns. Trends in Food Science and Technology, 2019, 91, 483-497.	7.8	49
50	Sonication-assisted Layer-by-Layer self-assembly nanoparticles for resveratrol delivery. Materials Science and Engineering C, 2019, 105, 110022.	3.8	9
51	Developing Cream Formulations: Renewed Interest in an Old Problem. Journal of Pharmaceutical Sciences, 2019, 108, 3240-3251.	1.6	18
52	Evolution of Hair Treatment and Care: Prospects of Nanotube-Based Formulations. Nanomaterials, 2019, 9, 903.	1.9	42
53	Nanotheranostic Pluronic-Like Polymeric Micelles: Shedding Light into the Dark Shadows of Tumors. Molecular Pharmaceutics, 2019, 16, 4757-4774.	2.3	18
54	Nanotechnological breakthroughs in the development of topical phytocompounds-based formulations. International Journal of Pharmaceutics, 2019, 572, 118787.	2.6	41

#	Article	IF	Citations
55	Subcutaneous delivery of biotherapeutics: challenges at the injection site. Expert Opinion on Drug Delivery, 2019, 16, 143-151.	2.4	31
56	Biomedical potential of clay nanotube formulations and their toxicity assessment. Expert Opinion on Drug Delivery, 2019, 16, 1169-1182.	2.4	44
57	First-time oral administration of resveratrol-loaded layer-by-layer nanoparticles to rats â€“ a pharmacokinetics study. Analyst, The, 2019, 144, 2062-2079.	1.7	25
58	Nanotechnology-based formulations for resveratrol delivery: Effects on resveratrol in vivo bioavailability and bioactivity. Colloids and Surfaces B: Biointerfaces, 2019, 180, 127-140.	2.5	82
59	Targeting Cancer Via Resveratrol-Loaded Nanoparticles Administration: Focusing on In Vivo Evidence. AAPS Journal, 2019, 21, 57.	2.2	24
60	Comparison of ELISA and HPLC-MS methods for the determination of exenatide in biological and biotechnology-based formulation matrices. Journal of Pharmaceutical Analysis, 2019, 9, 143-155.	2.4	19
61	Nanotechnology for the development of new cosmetic formulations. Expert Opinion on Drug Delivery, 2019, 16, 313-330.	2.4	103
62	Cellulose-Based Hydrogels in Topical Drug Delivery: A Challenge in Medical Devices. Polymers and Polymeric Composites, 2019, , 1205-1233.	0.6	2
63	Process analytical technologies and injectable drug products: Is there a future?. International Journal of Pharmaceutics, 2019, 554, 21-35.	2.6	17
64	Solvent-free synthesis of acetylated cashew gum for oral delivery system of insulin. Carbohydrate Polymers, 2019, 207, 601-608.	5.1	34
65	Nanostructured polymeric system based of cashew gum for oral admnistration of insulin. Revista Materia, 2019, 24, .	0.1	5
66	Sex differences in the gastrointestinal tract of rats and the implications for oral drug delivery. European Journal of Pharmaceutical Sciences, 2018, 115, 339-344.	1.9	32
67	Neoplastic Multifocal Skin Lesions: Biology, Etiology, and Targeted Therapies for Nonmelanoma Skin Cancers. Skin Pharmacology and Physiology, 2018, 31, 59-73.	1.1	12
68	Layer-by-Layer coated drug-core nanoparticles as versatile delivery platforms. , 2018, , 595-635.		9
69	Poloxamers, poloxamines and polymeric micelles: Definition, structure and therapeutic applications in cancer. Journal of Polymer Research, 2018, 25, 1.	1.2	100
70	The structure and diffusion behaviour of the 1:1 copper(II) complex of ethambutol in aqueous solution. Journal of Molecular Liquids, 2018, 262, 63-70.	2.3	3
71	Molecular dynamics simulations reveal the influence of dextran sulfate in nanoparticle formation with calcium alginate to encapsulate insulin. Journal of Biomolecular Structure and Dynamics, 2018, 36, 1255-1260.	2.0	7
72	In vitro multimodal-effect of Trichilia catigua A. Juss. (Meliaceae) bark aqueous extract in CNS targets. Journal of Ethnopharmacology, 2018, 211, 247-255.	2.0	20

#	Article	IF	Citations
73	Oxcarbazepine free or loaded PLGA nanoparticles as effective intranasal approach to control epileptic seizures in rodents. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 133, 309-320.	2.0	64
74	RNAi-based therapeutics for lung cancer: biomarkers, microRNAs, and nanocarriers. Expert Opinion on Drug Delivery, 2018, 15, 965-982.	2.4	15
75	Poly(lactic- co -glycolic acid) (PLGA) matrix implants. , 2018, , 375-402.		20
76	Halloysite clay nanotubes for life sciences applications: From drug encapsulation to bioscaffold. Advances in Colloid and Interface Science, 2018, 257, 58-70.	7.0	148
77	An egg yolkâ€™s phospholipid-pennyroyal nootropic nanoformulation modulates monoamino oxidase-A (MAO-A) activity in SH-SY5Y neuronal model. Journal of Functional Foods, 2018, 46, 335-344.	1.6	9
78	Bioequivalence of topical generic products. Part 2. Paving the way to a tailored regulatory system. European Journal of Pharmaceutical Sciences, 2018, 122, 264-272.	1.9	21
79	A practical framework for implementing Quality by Design to the development of topical drug products: Nanosystem-based dosage forms. International Journal of Pharmaceutics, 2018, 548, 385-399.	2.6	31
80	Polymeric micelles as a versatile tool in oral chemotherapy. , 2018, , 293-329.		4
81	A Tutorial for Developing a Topical Cream Formulation Based on the Quality by Design Approach. Journal of Pharmaceutical Sciences, 2018, 107, 2653-2662.	1.6	35
82	Bioequivalence of topical generic products. Part 1: Where are we now?. European Journal of Pharmaceutical Sciences, 2018, 123, 260-267.	1.9	23
83	Cellulose-Based Hydrogels in Topical Drug Delivery: A Challenge in Medical Devices. Polymers and Polymeric Composites, 2018, , 1-29.	0.6	1
84	Subcutaneous delivery of monoclonal antibodies: How do we get there?. Journal of Controlled Release, 2018, 286, 301-314.	4.8	138
85	miR-145-loaded micelleplexes as a novel therapeutic strategy to inhibit proliferation and migration of osteosarcoma cells. European Journal of Pharmaceutical Sciences, 2018, 123, 28-42.	1.9	24
86	Smart micelleplexes. , 2018, , 257-291.		6
87	Epithelialâ€mesenchymal transition and microRNAs: Challenges and future perspectives in oral cancer. Head and Neck, 2018, 40, 2304-2313.	0.9	22
88	In vivo biodistribution of antihyperglycemic biopolymer-based nanoparticles for the treatment of type 1 and type 2 diabetes. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 113, 88-96.	2.0	24
89	Political Islam in Turkey: From the Periphery to the State and Society Control. , 2017, , 35-56.		3
90	Ibuprofen nanocrystals developed by 22 factorial design experiment: A new approach for poorly water-soluble drugs. Saudi Pharmaceutical Journal, 2017, 25, 1117-1124.	1.2	33

#	Article	IF	Citations
91	Characterization of polymeric nanoparticles for intravenous delivery: Focus on stability. Colloids and Surfaces B: Biointerfaces, 2017, 150, 326-333.	2.5	20
92	Preparation methods and applications behind alginate-based particles. Expert Opinion on Drug Delivery, 2017, 14, 769-782.	2.4	79
93	Biopolymers and pilocarpine interaction study for use in drug delivery systems (DDS). Journal of Thermal Analysis and Calorimetry, 2017, 127, 1777-1785.	2.0	8
94	Smart micelleplexes as a new therapeutic approach for RNA delivery. Expert Opinion on Drug Delivery, 2017, 14, 353-371.	2.4	24
95	Methyl-Î²-cyclodextrin Inclusion Complex with Î²-Caryophyllene: Preparation, Characterization, and Improvement of Pharmacological Activities. ACS Omega, 2017, 2, 9080-9094.	1.6	36
96	Biodegradable polymeric nanostructures: design and advances in oral drug delivery for neurodegenerative disorders. , 2017, , 61-86.		5
97	Preparation and Characterization of Mixed Polymeric Micelles as a Versatile Strategy for Meloxicam Oral Administration. Letters in Drug Design and Discovery, 2017, 14, .	0.4	3
98	Preparation of Drug-Loaded Polymeric Nanoparticles. , 2017, , 171-214.		0
99	Sex differences in excipient effects: Enhancement in ranitidine bioavailability in the presence of polyethylene glycol in male, but not female, rats. International Journal of Pharmaceutics, 2016, 506, 237-241.	2.6	12
100	Biopharmaceutical evaluation of epigallocatechin gallate-loaded cationic lipid nanoparticles (EGCG-LNs): In vivo , in vitro and ex vivo studies. International Journal of Pharmaceutics, 2016, 502, 161-169.	2.6	101
101	Dual chitosan/albumin-coated alginate/dextran sulfate nanoparticles for enhanced oral delivery of insulin. Journal of Controlled Release, 2016, 232, 29-41.	4.8	168
102	Recent Advances in Nucleic Acid-Based Delivery: From Bench to Clinical Trials in Genetic Diseases. Journal of Biomedical Nanotechnology, 2016, 12, 841-862.	0.5	19
103	Diclofenac-Î²-cyclodextrin for colonic drug targeting: In vivo performance in rats. International Journal of Pharmaceutics, 2016, 500, 366-370.	2.6	9
104	Gumsâ€™ based delivery systems: Review on cashew gum and its derivatives. Carbohydrate Polymers, 2016, 147, 188-200.	5.1	98
105	Impact of the in vitro gastrointestinal passage of biopolymer-based nanoparticles on insulin absorption. RSC Advances, 2016, 6, 20155-20165.	1.7	14
106	Ocular Drug Delivery - New Strategies for Targeting Anterior and Posterior Segments of the Eye. Current Pharmaceutical Design, 2016, 22, 1135-1146.	0.9	51
107	Development and Validation of a New Method to Quantify Pilocarpine in Tablets by HPLC-DAD. Current Pharmaceutical Analysis, 2016, 12, 315-324.	0.3	1
108	Probing insulin bioactivity in oral nanoparticles produced by ultrasonication-assisted emulsification/internal gelation. International Journal of Nanomedicine, 2015, 10, 5865.	3.3	31

#	Article	IF	Citations
109	Improvements in Topical Ocular Drug Delivery Systems: Hydrogels and Contact Lenses. Journal of Pharmacy and Pharmaceutical Sciences, 2015, 18, 683.	0.9	30
110	Sonication-Assisted Layer-by-Layer Assembly for Low Solubility Drug Nanoformulation. ACS Applied Materials & Interfaces, 2015, 7, 11972-11983.	4.0	43
111	Transport properties in aqueous ethambutol dihydrochloride. International Journal of Pharmaceutics, 2015, 479, 306-311.	2.6	5
112	Molecular interaction governing solubility and release profiles in supramolecular systems containing fenbufen, pluronics and cyclodextrins. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2015, 81, 395-407.	0.9	10
113	Novel serine-based gemini surfactants as chemical permeation enhancers of local anesthetics: A comprehensive study on structureâ€“activity relationships, molecular dynamics and dermal delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 93, 205-213.	2.0	17
114	Diffusion coefficients of Î²-cyclodextrin sulfated sodium salt in aqueous solutions. Journal of Chemical Thermodynamics, 2015, 87, 117-121.	1.0	3
115	Why most oral insulin formulations do not reach clinical trials. Therapeutic Delivery, 2015, 6, 973-987.	1.2	39
116	Recent advances in characterization of nonviral vectors for delivery of nucleic acids: impact on their biological performance. Expert Opinion on Drug Delivery, 2015, 12, 27-39.	2.4	19
117	Polymeric micelles for oral drug administration enabling locoregional and systemic treatments. Expert Opinion on Drug Delivery, 2015, 12, 297-318.	2.4	90
118	Lysine-based surfactants as chemical permeation enhancers for dermal delivery of local anesthetics. International Journal of Pharmaceutics, 2014, 474, 212-222.	2.6	18
119	Effect of Cyclodextrins and pH on the permeation of tetracaine: Supramolecular assemblies and release behavior. International Journal of Pharmaceutics, 2014, 466, 349-358.	2.6	15
120	Supramolecular gels of poly-Î±-cyclodextrin and PEO-based copolymers for controlled drug release. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 87, 579-588.	2.0	35
121	Intestinal absorption of insulin nanoparticles: Contribution of M cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 1139-1151.	1.7	73
122	Influence of feeding regimens on rat gut fluids and colonic metabolism of diclofenac-Î²-cyclodextrin. Carbohydrate Polymers, 2014, 112, 758-764.	5.1	5
123	Crystalline forms of nonprotein drugs filed in Brazil from 1995â€“2005. Pharmaceutical Patent Analyst, 2014, 3, 151-161.	0.4	0
124	Advance in Methods Studying the Pharmacokinetics of Polyphenols. Current Drug Metabolism, 2014, 15, 96-115.	0.7	10
125	Intestinal Uptake of Insulin Nanoparticles: Facts or Myths?. Current Pharmaceutical Biotechnology, 2014, 15, 629-638.	0.9	21
126	Syringeable Self-Assembled Cyclodextrin Gels for Drug Delivery. Current Topics in Medicinal Chemistry, 2014, 14, 494-509.	1.0	27

#	Article	IF	Citations
127	Ultrasonication of insulin-loaded microgel particles produced by internal gelation: Impact on particle's size and insulin bioactivity. Carbohydrate Polymers, 2013, 98, 1397-1408.	5.1	23
128	Effect of HP-Î²-cyclodextrin in the diffusion behaviour of hydrocortisone in aqueous solutions at T=298.15K. International Journal of Pharmaceutics, 2013, 441, 352-355.	2.6	6
129	Mass transport techniques as a tool for a better understanding of the structure of l-Dopa in aqueous solutions. International Journal of Pharmaceutics, 2013, 447, 293-297.	2.6	18
130	The systems containing clays and clay minerals from modified drug release: A review. Colloids and Surfaces B: Biointerfaces, 2013, 103, 642-651.	2.5	170
131	Gamma scintigraphy in the analysis of ketoprofen behaviour from matrix tablets. International Journal of Pharmaceutics, 2013, 448, 298-304.	2.6	3
132	Poloxamineâ€“Cyclodextrinâ€“Simvastatin Supramolecular Systems Promote Osteoblast Differentiation of Mesenchymal Stem Cells. Macromolecular Bioscience, 2013, 13, 723-734.	2.1	32
133	Nanoparticles for Oral Delivery of Insulin. Advances in Predictive, Preventive and Personalised Medicine, 2013, , 109-125.	0.6	0
134	Microwave synthesis and in vitro stability of diclofenac-Î²-cyclodextrin conjugate for colon delivery. Carbohydrate Polymers, 2013, 93, 512-517.	5.1	18
135	Encapsulation of DNA in Macroscopic and Nanosized Calcium Alginate Gel Particles. Langmuir, 2013, 29, 15926-15935.	1.6	26
136	In vitrorelease of ketoprofen from hydrophilic matrix tablets containing cellulose polymer mixtures. Drug Development and Industrial Pharmacy, 2013, 39, 1651-1662.	0.9	10
137	Development of a Doxazosin and Finasteride Transdermal System for Combination Therapy of Benign Prostatic Hyperplasia. Journal of Pharmaceutical Sciences, 2013, 102, 4057-4064.	1.6	14
138	Restoration of direct pathway glycogen synthesis flux in the STZ-diabetes rat model by insulin administration. American Journal of Physiology - Endocrinology and Metabolism, 2012, 303, E875-E885.	1.8	20
139	Single and mixed poloxamine micelles as nanocarriers for solubilization and sustained release of ethoxzolamide for topical glaucoma therapy. Journal of the Royal Society Interface, 2012, 9, 2059-2069.	1.5	76
140	Mucus thickness in the gastrointestinal tract of laboratory animals. Journal of Pharmacy and Pharmacology, 2012, 64, 218-227.	1.2	62
141	Syringeable Pluronicâ€“Î±-cyclodextrin supramolecular gels for sustained delivery of vancomycin. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 80, 103-112.	2.0	80
142	Effects of an oral insulin nanoparticle administration on hepatic glucose metabolism assessed by13C and2H isotopomer analysis. Journal of Microencapsulation, 2012, 29, 167-176.	1.2	3
143	Preparation of Calcium Alginate Nanoparticles Using Water-in-Oil (W/O) Nanoemulsions. Langmuir, 2012, 28, 4131-4141.	1.6	103
144	Evaluation of hepatic glucose metabolism via gluconeogenesis and glycogenolysis after oral administration of insulin nanoparticles. Drug Development and Industrial Pharmacy, 2012, 38, 1441-1450.	0.9	9

#	Article	IF	Citations
145	Hydrophilic acrylic hydrogels with built-in or pendant cyclodextrins for delivery of anti-glaucoma drugs. Carbohydrate Polymers, 2012, 88, 977-985.	5.1	40
146	Bioinspired Imprinted PHEMA-Hydrogels for Ocular Delivery of Carbonic Anhydrase Inhibitor Drugs. Biomacromolecules, 2011, 12, 701-709.	2.6	113
147	New delivery systems to improve the bioavailability of resveratrol. Expert Opinion on Drug Delivery, 2011, 8, 973-990.	2.4	107
148	Cyclodextrins and ternary complexes: technology to improve solubility of poorly soluble drugs. Brazilian Journal of Pharmaceutical Sciences, 2011, 47, 665-681.	1.2	126
149	Hepatic and renal toxicities of indomethacin acid, salt form and complexed forms with hydroxypropylâ€î²â€cyclodextrin on Wistar rats after oral administration. Fundamental and Clinical Pharmacology, 2011, 25, 599-607.	1.0	7
150	Receptor-based biomimetic NVP/DMA contact lenses for loading/eluting carbonic anhydrase inhibitors. Journal of Membrane Science, 2011, 383, 60-69.	4.1	37
151	Mucoadhesive platforms for targeted delivery to the colon. International Journal of Pharmaceutics, 2011, 420, 11-19.	2.6	36
152	Solid Dispersions of Imidazolidinedione by PEG and PVP Polymers with Potential Antischistosomal Activities. AAPS PharmSciTech, 2011, 12, 401-410.	1.5	22
153	Transport properties of aqueous solutions of sodium alginate at 298.15K. Food Chemistry, 2011, 125, 1213-1218.	4.2	19
154	Facilitated nanoscale delivery of insulin across intestinal membrane models. International Journal of Pharmaceutics, 2011, 412, 123-131.	2.6	107
155	The Role of l-arginine in Inclusion Complexes of Omeprazole with Cyclodextrins. AAPS PharmSciTech, 2010, 11, 233-240.	1.5	33
156	A Comprehensive Development Strategy in Buccal Drug Delivery. AAPS PharmSciTech, 2010, 11, 1703-1712.	1.5	15
157	Assessment of the in-vivo drug release from pellets film-coated with a dispersion of high amylose starch and ethylcellulose for potential colon delivery. Journal of Pharmacy and Pharmacology, 2010, 62, 55-61.	1.2	17
158	An investigation into the role of mucus thickness on mucoadhesion in the gastrointestinal tract of pig. European Journal of Pharmaceutical Sciences, 2010, 40, 335-341.	1.9	61
159	Pharmacological effect of orally delivered insulin facilitated by multilayered stable nanoparticles. European Journal of Pharmaceutical Sciences, 2010, 41, 556-563.	1.9	106
160	Effects of galactose on direct and indirect pathway estimates of hepatic glycogen synthesis. Metabolic Engineering, 2010, 12, 552-560.	3.6	13
161	Interactions between DNA and Nonionic Ethylene Oxide Surfactants are Predominantly Repulsive. Langmuir, 2010, 26, 13102-13109.	1.6	13
162	Diffusion Coefficients of (Copper Chloride + Theophylline + Water) at Temperatures of (298 and 310) K. Journal of Chemical & Engineering Data, 2010, 55, 2192-2194.	1.0	7

#	Article	IF	Citations
163	Influence of the coating formulation on enzymatic digestibility and drug release from 5-aminosalicylic acid pellets coated with mixtures of high-amylose starch and SureleaseÂ® intended for colon-specific drug delivery. Drug Development and Industrial Pharmacy, 2010, 36, 161-172.	0.9	25
164	Combining strategies to optimize a gel formulation containing miconazole: the influence of modified cyclodextrin on textural properties and drug release. Drug Development and Industrial Pharmacy, 2010, 36, 705-714.	0.9	7
165	Diffusion coefficients of the ternary system (2-hydroxypropyl-Î²-cyclodextrin+caffeine+water) at T=298.15K. Journal of Chemical Thermodynamics, 2009, 41, 1324-1328.	1.0	31
166	Evaluation of gastric toxicity of indomethacin acid, salt form and complexed forms with hydroxypropylâ€Î²â€cyclodextrin on Wistar rats: histopathologic analysis. Fundamental and Clinical Pharmacology, 2009, 23, 747-755.	1.0	6
167	Colloidal carrier integrating biomaterials for oral insulin delivery: Influence of component formulation on physicochemical and biological parameters. Acta Biomaterialia, 2009, 5, 2475-2484.	4.1	66
168	Binary Mutual Diffusion Coefficients of Isoniazid Aqueous Solutions at (298.15 and 310.15) K. Journal of Chemical & Engineering Data, 2009, 54, 3235-3237.	1.0	12
169	In vitro evaluation of natural and methylated cyclodextrins as buccal permeation enhancing system for omeprazole delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 71, 339-345.	2.0	43
170	Starch-based coatings for colon-specific drug delivery. Part I: The influence of heat treatment on the physico-chemical properties of high amylose maize starches. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 72, 574-586.	2.0	46
171	Starch-based coatings for colon-specific delivery. Part II: Physicochemical properties and in vitro drug release from high amylose maize starch films. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 72, 587-594.	2.0	51
172	Design for optimization of nanoparticles integrating biomaterials for orally dosed insulin. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 73, 25-33.	2.0	85
173	Diffusion Coefficients of the Ternary System Î²-Cyclodextrin + Caffeine + Water at 298.15 K. Journal of Chemical & Engineering Data, 2009, 54, 115-117.	1.0	36
174	New insight into the discrimination between omeprazole enantiomers by cyclodextrins in aqueous solution. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2008, 62, 345-351.	1.6	2
175	Nanoparticulate biopolymers deliver insulin orally eliciting pharmacological response. Journal of Pharmaceutical Sciences, 2008, 97, 5290-5305.	1.6	84
176	Preparation and Solid-State Characterization of Inclusion Complexes Formed Between Miconazole and Methyl-Î²-Cyclodextrin. AAPS PharmSciTech, 2008, 9, 1102-1109.	1.5	76
177	Toxicological assessment of orally delivered nanoparticulate insulin. Nanotoxicology, 2008, 2, 205-217.	1.6	32
178	Polyelectrolyte Biomaterial Interactions Provide Nanoparticulate Carrier for Oral Insulin Delivery. Drug Delivery, 2008, 15, 127-139.	2.5	73
179	Some Transport Properties of Î³-Cyclodextrin Aqueous Solutions at (298.15 and 310.15) K. Journal of Chemical & Engineering Data, 2008, 53, 755-759.	1.0	38
180	Strategies Toward the Improved Oral Delivery of Insulin Nanoparticles via Gastrointestinal Uptake and Translocation. BioDrugs, 2008, 22, 223-237.	2.2	59

#	Article	IF	Citations
181	Estudos de mucoadesÃ£o no trato gastrointestinal para o aumento da biodisponibilidade oral de fÃ¡rmacos. BJPS: Brazilian Journal of Pharmaceutical Sciences, 2008, 44, .	0.5	1
182	Mucoadhesion and the Gastrointestinal Tract. Critical Reviews in Therapeutic Drug Carrier Systems, 2008, 25, 207-258.	1.2	66
183	Solid-state characterization and dissolution profiles of the inclusion complexes of omeprazole with native and chemically modified Î²-cyclodextrin. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 67, 531-539.	2.0	113
184	Insulin-Loaded Nanoparticles are Prepared by Alginate Ionotropic Pre-Gelation Followed by Chitosan Polyelectrolyte Complexation. Journal of Nanoscience and Nanotechnology, 2007, 7, 2833-2841.	0.9	200
185	Binary Mutual Diffusion Coefficients of Aqueous Solutions of Î±-Cyclodextrin, 2-Hydroxypropyl-Î±-cyclodextrin, and 2-Hydroxypropyl-Î²-cyclodextrin at Temperatures from (298.15 to) Tj ETQq1 1 0.784314 rgBT /O	1.0	50
186	Oral Bioavailability of Insulin Contained in Polysaccharide Nanoparticles. Biomacromolecules, 2007, 8, 3054-3060.	2.6	236
187	Oral administration of peptides and proteins: nanoparticles and cyclodextrins as biocompatible delivery systems. Nanomedicine, 2007, 2, 183-202.	1.7	47
188	Alginate microparticles as novel carrier for oral insulin delivery. Biotechnology and Bioengineering, 2007, 96, 977-989.	1.7	65
189	Cyclodextrin Multicomponent Complexation and Controlled Release Delivery Strategies to Optimize the Oral Bioavailability of Vinpocetine. Journal of Pharmaceutical Sciences, 2007, 96, 2018-2028.	1.6	28
190	Nanoparticulate delivery system for insulin: Design, characterization and in vitro/in vivo bioactivity. European Journal of Pharmaceutical Sciences, 2007, 30, 392-397.	1.9	126
191	Interaction of Omeprazole with a Methylated Derivative of Î²-Cyclodextrin: Phase Solubility, NMR Spectroscopy and Molecular Simulation. Pharmaceutical Research, 2007, 24, 377-389.	1.7	68
192	Alginate/Chitosan Nanoparticles are Effective for Oral Insulin Delivery. Pharmaceutical Research, 2007, 24, 2198-2206.	1.7	522
193	Preparation and physicochemical characterization of omeprazole:methyl-beta-cyclodextrin inclusion complex in solid state. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2007, 57, 173-177.	1.6	38
194	Evaluation of host-guest complex formation between a benzimidazolic derivative and cyclodextrins by UV-VIS spectrophotometry and differential scanning calorimetry. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2007, 57, 531-535.	1.6	9
195	Effect of Chitosan-Coated Alginate Microspheres on the Permeability of Caco-2 Cell Monolayers. Drug Development and Industrial Pharmacy, 2006, 32, 1079-1088.	0.9	20
196	Binary Mutual Diffusion Coefficients of Aqueous Solutions of Î²-Cyclodextrin at Temperatures from 298.15 to 312.15 K. Journal of Chemical & Engineering Data, 2006, 51, 1368-1371.	1.0	69
197	LiberaÃ§Ã£o especÃfica de fÃ¡rmacos para administraÃ§Ã£o no cÃ³lon por via oral. I - O cÃ³lon como local de liberaÃ§Ã£o de fÃ¡rmacos. BJPS: Brazilian Journal of Pharmaceutical Sciences, 2006, 42, 319-335.	0.5	8
198	Design of insulin-loaded alginate nanoparticles: Influence of the calcium ion on polymer gel matrix properties. Chemical Industry and Chemical Engineering Quarterly, 2006, 12, 47-52.	0.4	28

#	Article	IF	Citations
199	LiberaÃ§Ã£o especÃfica de fÃ¡rmacos no cÃ³lon por via oral. II - Tipos de sistemas utilizados. BJPS: Brazilian Journal of Pharmaceutical Sciences, 2006, 42, 337-355.	0.5	4
200	Characterization of insulin-loaded alginate nanoparticles produced by ionotropic pre-gelation through DSC and FTIR studies. Carbohydrate Polymers, 2006, 66, 1-7.	5.1	428
201	Development and characterization of new insulin containing polysaccharide nanoparticles. Colloids and Surfaces B: Biointerfaces, 2006, 53, 193-202.	2.5	212
202	Conformational study of ketoprofen by combined DFT calculations and Raman spectroscopy. International Journal of Pharmaceutics, 2006, 307, 56-65.	2.6	70
203	Alginate microspheres prepared by internal gelation: Development and effect on insulin stability. International Journal of Pharmaceutics, 2006, 311, 1-10.	2.6	176
204	Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine, 2006, 2, 8-21.	1.7	1,080
205	Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine: Nanotechnology, Biology, and Medicine, 2006, 2, 53-65.	1.7	193
206	Review and current status of emulsion/dispersion technology using an internal gelation process for the design of alginate particles. Journal of Microencapsulation, 2006, 23, 245-257.	1.2	182
207	Development and Comparison of Different Nanoparticulate Polyelectrolyte Complexes as Insulin Carriers. International Journal of Peptide Research and Therapeutics, 2006, 12, 131-138.	0.9	144
208	Insulin encapsulation in reinforced alginate microspheres prepared by internal gelation. European Journal of Pharmaceutical Sciences, 2006, 29, 148-159.	1.9	108
209	Development and validation of a rapid reversed-phase HPLC method for the determination of insulin from nanoparticulate systems. Biomedical Chromatography, 2006, 20, 898-903.	0.8	90
210	Influence of Cellulose Ether Mixtures on Ibuprofen Release: MC25, HPC and HPMC K100M. Pharmaceutical Development and Technology, 2006, 11, 213-228.	1.1	36
211	Design of pectin beads for oral protein delivery. Chemical Industry and Chemical Engineering Quarterly, 2006, 12, 24-30.	0.4	2
212	Insulin release from alginate microspheres reinforced with dextran sulfate. Chemical Industry and Chemical Engineering Quarterly, 2006, 12, 40-46.	0.4	6
213	Compaction, compression and drug release properties of diclofenac sodium and ibuprofen pellets comprising xanthan gum as a sustained release agent. International Journal of Pharmaceutics, 2005, 295, 15-27.	2.6	79
214	Role of Cellulose Ether Polymers on Ibuprofen Release from Matrix Tablets. Drug Development and Industrial Pharmacy, 2005, 31, 653-665.	0.9	33
215	Multicomponent complex formation between vinpocetine, cyclodextrins, tartaric acid and water-soluble polymers monitored by NMR and solubility studies. European Journal of Pharmaceutical Sciences, 2005, 24, 1-13.	1.9	77
216	Chitosan-reinforced alginate microspheres obtained through the emulsification/internal gelation technique. European Journal of Pharmaceutical Sciences, 2005, 25, 31-40.	1.9	209

#	Article	IF	Citations
217	In vitro controlled release of vinpocetineâ€“cyclodextrinâ€“tartaric acid multicomponent complexes from HPMC swellable tablets. Journal of Controlled Release, 2005, 103, 325-339.	4.8	36
218	Compatibility Studies Between Ibuprofen or Ketoprofen with Cellulose Ether Polymer Mixtures Using Thermal Analysis. Drug Development and Industrial Pharmacy, 2005, 31, 943-949.	0.9	20
219	Microencapsulation of hemoglobin in chitosan-coated alginate microspheres prepared by emulsification/internal gelation. AAPS Journal, 2005, 7, E903-E913.	2.2	88
220	Compaction, compression and drug release characteristics of xanthan gum pellets of different compositions. European Journal of Pharmaceutical Sciences, 2004, 21, 271-281.	1.9	34
221	Influence of cellulose ether polymers on ketoprofen release from hydrophilic matrix tablets. European Journal of Pharmaceutics and Biopharmaceutics, 2004, 58, 51-59.	2.0	127
222	Multimodal molecular encapsulation of nicardipine hydrochloride by Î²-cyclodextrin, hydroxypropyl-Î²-cyclodextrin and triacetyl-Î²-cyclodextrin in solution. Structural studies by 1H NMR and ROESY experiments. European Journal of Pharmaceutical Sciences, 2003, 18, 285-296.	1.9	103
223	Physicochemical investigation of the effects of water-soluble polymers on vinpocetine complexation with Î²-cyclodextrin and its sulfobutyl ether derivative in solution and solid state. European Journal of Pharmaceutical Sciences, 2003, 20, 253-266.	1.9	76
224	Hydrophilic and hydrophobic cyclodextrins in a new sustained release oral formulation of nicardipine: in vitro evaluation and bioavailability studies in rabbits. Journal of Controlled Release, 2003, 88, 127-134.	4.8	35
225	A simple method for nicardipine hydrochloride quantification in plasma using solid-phase extraction and reversed-phase high-performance liquid chromatography. Biomedical Chromatography, 2003, 17, 33-38.	0.8	15
226	Effect of Polymer Hydration on the Kinetic Release of Drugs: A Study of Ibuprofen and Ketoprofen in HPMC Matrices. Drug Development and Industrial Pharmacy, 2003, 29, 289-297.	0.9	17
227	Investigation and Physicochemical Characterization of Vinpocetine-Sulfobutyl Ether .BETA.-Cyclodextrin Binary and Ternary Complexes. Chemical and Pharmaceutical Bulletin, 2003, 51, 914-922.	0.6	86
228	Effect of the Hydrophobic Nature of Triacetyl-.BETA.-cyclodextrin on the Complexation with Nicardipine Hydrochloride: Physicochemical and Dissolution Properties of the Kneaded and Spray-dried Complexes.. Chemical and Pharmaceutical Bulletin, 2002, 50, 1597-1602.	0.6	31
229	Physicochemical characterization and in vitro dissolution behavior of nicardipineâ€“cyclodextrins inclusion compounds. European Journal of Pharmaceutical Sciences, 2002, 15, 79-88.	1.9	202
230	Physical properties of chitosan pellets produced by extrusionâ€“spheronisation: influence of formulation variables. International Journal of Pharmaceutics, 2002, 246, 153-169.	2.6	58
231	The Cyclodextrins as Modelling Agents of Drug Controlled Release. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2002, 44, 79-85.	1.6	7
232	Title is missing!. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2002, 44, 251-256.	1.6	20
233	Molecular Modelling and 1H-NMR: Ultimate Tools for the Investigation of Tolbutamide: .BETA.-Cyclodextrin and Tolbutamide: Hydroxypropyl-.BETA.-Cyclodextrin Complexes.. Chemical and Pharmaceutical Bulletin, 2001, 49, 1251-1256.	0.6	55
234	Influence of the Preparation Method on the Physicochemical Properties of Tolbutamide/Cyclodextrin Binary Systems. Drug Development and Industrial Pharmacy, 2001, 27, 523-532.	0.9	36

#	Article	IF	Citations
235	Oral bioavailability and hypoglycaemic activity of tolbutamide/cyclodextrin inclusion complexes. International Journal of Pharmaceutics, 2000, 202, 165-171.	2.6	56
236	The Influence of Diluent on the Release of Theophylline from Hydrophilic Matrix Tablets. Drug Development and Industrial Pharmacy, 2000, 26, 1125-1128.	0.9	17
237	DEVELOPMENT AND VALIDATION OF AN HPLC METHOD FOR SIMULTANEOUS DETERMINATION OF CIS- AND TRANS- PERMETHRIN AND PIPERONYL BUTOXIDE IN PHARMACEUTICAL DOSAGE FORMS. Journal of Liquid Chromatography and Related Technologies, 1999, 22, 1867-1876.	0.5	10
238	Inclusion complexation of tolbutamide with Î²-cyclodextrin and hydroxypropyl-Î²-cyclodextrin. International Journal of Pharmaceutics, 1996, 129, 63-71.	2.6	94
239	Using a particle counter to assess in vitro dissolution studies. International Journal of Pharmaceutics, 1996, 131, 273-276.	2.6	0
240	Alginates: Micro- and Nanoparticles. , 0, , 112-125.		0
241	Application of nanotechnology in management and treatment of diabetic wounds. Journal of Drug Targeting, 0, , 1-21.	2.1	8